Sharpen that competitive edge — PTI guides pharma on effective PAT/QbD best practice
![](/46/pdcnewsitem/03/82/26/1507PTI%20Emil%20Ciurczak.jpg)
Easy-access webinar e-course from PTI helps pharmaceutical manufacturers implement successful Quality by Design strategies.
Pharmaceutical Training International (PTI) continues its easy-access series of webinar e-courses with guidance on implementing an effective Quality by Design (QbD) approach. Professionals working both directly and indirectly in pharmaceutical manufacturing will benefit from industry expert, Emil W. Ciurczak’s, decades of experience in the pharmaceutical industry and expertise in analytical method development and improvement. Entitled ‘The QbD outlook in pharmaceutical manufacturing’ the e-course will take place at 2:30 PM (UK) on Wednesday 9 December, and show participants how an effective QbD strategy can minimise costs and maximise efficiencies in manufacturing processes.
As the pharmaceutical market becomes ever more competitive, manufacturers need to ensure their processes are as time- and cost-effective as possible. This requires a thorough understanding of the chemical and mechanical properties of the elements used to make a pharmaceutical product, as well as the manufacturing processes involved. In this webinar e-course, Emil Ciurczak will provide a complete overview of implementing QbD, including the economic reasons, regulatory requirements, technologies, concepts for software and compliance, and best practices to successfully roll out QbD with minimal risk. He will also address specific queries in an interactive question and answer session at the end of the webinar. Participants will be able to use the knowledge gained from this course to develop a QbD strategy for their own manufacturing processes, improving quality, reducing variance and time to market, as well as HVAC and materials costs.
PTI’s Managing Director, Rosie Bernard, comments: “In today’s market, pharmaceutical manufacturers really need an edge to stay competitive and maximise their return on investment. At PTI, we understand that the correct implementation of a Quality by Design strategy can make a real difference. In this latest session of our series of webinar e-courses, we provide easy access to Emil’s considerable experience in pharma. Having worked in the industry since the 1970s, he will ensure all who participate in the session leave with a thorough understanding of QbD and the considerations needed to make it successful.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance